Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.

Published

Journal Article (Review)

Angiogenesis, the development and proliferation of new blood vessels, is critical for the growth of tumors. The process of new blood vessel formation is under complex control from a variety of pro- and anti-angiogenesis factors. By identifying and understanding these factors, new therapies have been developed to inhibit tumor growth and survival by blocking tumor-related angiogenesis. Recent success with the monoclonal antibody against vascular endothelial growth factor (VEGF; bevacizumab) in a large, randomized, phase III study has provided a critical proof of principle for this therapeutic area. This review will outline the biology of angiogenesis in colorectal cancer and discuss the current status of angiogenesis inhibition in its treatment.

Full Text

Duke Authors

Cited Authors

  • Collins, TS; Hurwitz, HI

Published Date

  • February 2005

Published In

Volume / Issue

  • 32 / 1

Start / End Page

  • 61 - 68

PubMed ID

  • 15726507

Pubmed Central ID

  • 15726507

International Standard Serial Number (ISSN)

  • 0093-7754

Digital Object Identifier (DOI)

  • 10.1053/j.seminoncol.2004.09.026

Language

  • eng

Conference Location

  • United States